Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Cancer Anorexia-Cachexia Syndrome (CACS) Market Through 2034?
The market for the cancer anorexia-cachexia syndrome (cacs) has seen dynamic expansion in the past few years. With a progression from $3.51 billion in 2024, it is anticipated to climb up to $3.88 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.7%. Factors influencing this advancement in the historic period include the escalating occurrence of cancer, heightened cognizance among medical professionals, an emphasis on improving life quality for cancer patients, widening of clinical trials, and the increase in cooperative efforts and alliances in the pharmaceutical sector.
The market size for the cancer anorexia-cachexia syndrome (cacs) is projected to experience swift expansion in the upcoming years, with a valuation predicted to reach$5.79 billion in 2029″ at a compound annual growth rate (CAGR) of 10.5%. The momentum during the forecast period can be credited to improved cancer survival rates, growing investment in oncology support care, advancements in personalized medicine, intensified focus on multimodal treatments, and the developing health care infrastructure. The forecast period will also witness major trends such as progress in palliative care, the creation of focused therapies, technological innovation in drug delivery systems, incorporation of AI in drug formation, and tailor-made medicine.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Cancer Anorexia-Cachexia Syndrome (CACS) Market?
The expected rise in cancer cases is projected to steer the expansion of the cancer anorexia-cachexia syndrome market. This encompasses a range of diseases marked by uninhibited cell proliferation and spread within the body, broadly defined as cancer. The increasing global incidence of cancer is due to a multitude of factors such as an aging demographic, modifications in lifestyle, environmental factors, enhanced methods of detection, increased awareness, genetic susceptibility, and infections associated with specific cancer types. The cancer anorexia-cachexia syndrome (CACS) assists in managing severe weight loss and malnutrition commonly associated with cancer patients, aiming to better their general life quality and treatment results. For example, a study released by Macmillan Cancer Support, a UK charity, in August 2024 indicated that over 3 million people have cancer in the UK. This statistic is predicted to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the surge in cancer incidence is pushing the expansion of the cancer anorexia-cachexia syndrome market.
Which Key Market Segments Comprise the Cancer Anorexia-Cachexia Syndrome (CACS) Market and Drive Its Revenue Growth?
The cancer anorexia-cachexia syndrome (cacs)market covered in this report is segmented –
1) By Indication: Weight Loss Prevention; Appetite Loss; Muscle Wasting; Inflammation; Other Indications
2) By Therapeutics: Progestogen; Corticosteroid; Combination Therapy; Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants; Anti-inflammatory Agents; Hormone Therapies; Cannabinoids; Other Mechanism Of Actions
4) By Route of Administration: Oral; Intravenous; Subcutaneous; Transdermal; Other Route of Administration
5) By Application: Hospitals; Clinics; Home Care
Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements; Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants; Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents; Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs; Cytokine Inhibitors
5) By Other Indications: Combination Therapies; Supportive Care Interventions
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp
Which Areas Are Leading Regions in the Cancer Anorexia-Cachexia Syndrome (CACS) Market Expansion Across the Globe?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theCancer Anorexia-Cachexia Syndrome (CACS) Market Direction?
Predominant corporations in the field of the cancer anorexia-cachexia syndrome market are centering their efforts on creating novel solutions, such as monoclonal antibody therapies. These therapies are expected to increase the effectiveness of treatments, raise patient outcomes, and answer unsatisfied clinical requirements. Monoclonal antibody therapies consist of treatments that employ antibodies produced in a lab designed to target unique antigens on cancer cells, enabling the immune system to identify and counter them more efficiently. For instance, Pfizer Inc., a pharmaceutical and biotechnology entity based in the US, reported positive findings from a Phase II clinical trial of ponsegromab, a monoclonal antibody aiming at Growth/Differentiation Factor 15 (GDF-15) in September 2024. The encouraging data from this research provides a glimmer of hope for a fresh treatment path for patients battling this debilitating ailment, currently having very few effective treatments. The results of the Phase 2 trial indicate substantial advancements in tackling the underlying inflammatory processes leading to muscle deterioration and weight decrease in cancer patients. Such an approach aspires to not only enhance physical function but to also amplify the overall life quality for cancer patients, representing a crucial advancement in oncology care.
View the full report here:
How Is the Cancer Anorexia-Cachexia Syndrome (CACS) Market Conceptually Defined?
Cancer anorexia-cachexia syndrome (CACS) is a multifactorial condition commonly seen in cancer patients, marked by severe metabolic disturbances. It involves a combination of inflammatory responses, hormonal changes, and altered nutrient utilization, often leading to poor prognosis and treatment resistance.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model